跳至主要内容
临床试验/NCT02241564
NCT02241564已完成不适用

Follow-up of Malignancies in Transplanted Patients

Uppsala University1 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
95
试验地点
1
主要终点
Patient survival

研究概览

简要总结

The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients willing and capable of giving written informed consent of participation in the project
  • Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma)

排除标准

  • Patients with a primary liver cancer as cause of the transplantation

研究组 & 干预措施

Malignancy post transplantation

干预措施: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection (Other)

Malignancy post transplantation

干预措施: Switch from calcineurin inhibitor to an mTOR inhibitor (Drug)

结局指标

主要结局

Patient survival

时间窗: 12 months, 2 years, 3 years

After inclusion

次要结局

  • ImmuKnow Assay value(12 months)
  • Graft survival(12 months, 2 years, 3 years)
  • Tumour progression/regression/reoccurrence(12 months, 2 years, 3 years)
  • Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor(3 years)
  • Kidney function(12 months, 2 years, 3 years)

研究者

发起方
Uppsala University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tomas Lorant

Associate professor

Uppsala University

研究点 (1)

Loading locations...

相似试验

Malignancies in Transplanted Patients | 临床试验